Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial

Authors

Tithi Biswas, Case Western Reserve University
Rohin Gawdi, Wake Forest University
Charulata Jindal, Harvard University
Sharanya Iyer, Case Western Reserve University
Kylie H. Kang, Washington University School of Medicine in St. Louis
David Bajor, Case Western Reserve University
Mitchell Machtay, Penn State University
Yuk Ming Choi, Signify Health, Dallas
Jimmy T. Efird, DVAHCS, Durham

Journal

Journal of Thoracic Disease

Publication Date

10-1-2021

Volume

13

Issue

10

First Page

5617

Last Page

5626

Document Type

Open Access Publication

DOI

10.21037/jtd-21-1018

Rights and Permissions

Biswas T, Gawdi R, Jindal C, Iyer S, Kang KH, Bajor D, Machtay M, Choi YM, Efird JT. Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial. J Thorac Dis 2021;13(10):5617-5626. doi: 10.21037/jtd-21-1018

Recommended Citation

Biswas, Tithi; Gawdi, Rohin; Jindal, Charulata; Iyer, Sharanya; Kang, Kylie H.; Bajor, David; Machtay, Mitchell; Choi, Yuk Ming; and Efird, Jimmy T., "Pretreatment neutrophil-to-lymphocyte ratio as an important prognostic marker in stage III locally advanced non-small cell lung cancer: Confirmatory results from the PROCLAIM phase III clinical trial." Journal of Thoracic Disease. 13, 10. 5617 - 5626. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/11196